The National Health Service (NHS) is struggling to meet the increasing demand for weight loss services, according to experts. Doctors have raised concerns that patients are resorting to purchasing medications like Ozempic and Wegovy due to limited access to NHS services, leading to worries about the rise of medical tourism.

Novo Nordisk, the maker of Ozempic, is investing over $4 billion in expanding its manufacturing operations in the US. The pharmaceutical company plans to build a new plant in North Carolina to produce its diabetes drug Ozempic and weight-loss product Wegovy. This significant investment of $4.1 billion will go towards constructing a second filling and finishing facility in Clayton, North Carolina. Novo Nordisk is making this move to meet the increasing demand for its obesity and diabetes medications, which are administered through pre-filled pens and require weekly injections. This expansion in manufacturing capacity represents one of the largest investments in Novo Nordisk's history as it strives to keep pace with the growing market for its innovative drugs.

Senator Bernie Sanders is taking aim at the exorbitant prices of weight-loss drugs Ozempic and Wegovy, manufactured by a Danish pharmaceutical company. These drugs, which have become incredibly popular in the United States, are priced at a rate that is ten times higher than in other countries. Wegovy and Ozempic have become household names in America, often associated with celebrities like Oprah Winfrey and touted as life-changing by medical professionals. However, the high demand for these drugs, which are used not only by individuals with diabetes but also by those struggling with obesity, has highlighted a major issue in the American healthcare system - the cost of medication. Senator Sanders plans to question the CEO of the pharmaceutical company responsible for these drugs about the pricing disparity between the US and other countries. The inflated prices of Wegovy and Ozempic are seen as unacceptable, especially considering the significant impact they can have on individuals' health and well-being. The debate over the cost of these weight-loss drugs reflects a larger issue within the healthcare industry in the US, where medication prices often put a strain on individuals and families. Sanders' efforts to address this issue are part of a broader push for more affordable and accessible healthcare for all Americans.